|Bid||2.5600 x 900|
|Ask||2.5800 x 800|
|Day's Range||2.5400 - 2.6000|
|52 Week Range||1.6000 - 4.7000|
|Beta (3Y Monthly)||3.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.75|
Anyone researching Ardelyx, Inc. (NASDAQ:ARDX) might want to consider the historical volatility of the share price...
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
FREMONT, Calif., May 30, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2019 at 9:00 a.m. ET in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines.
Ardelyx (ARDX) delivered earnings and revenue surprises of -10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Fremont, California-based company said it had a loss of 42 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Two Pivotal Phase 3 readouts in 2H 2019 FREMONT, Calif. , May 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines ...
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It is doubtless a positive to see that the Ardelyx, Inc. (NASDAQ:ARDX) share price has gained some 43% in the last three months. Meanwhile over the last three years the stock has dropped hard. Tragically, the share price d...
The Fremont company expects results from two late-stage clinical trials in kidney failure patients later this year. The same drug is expected to face a regulatory decision in September for another condition.
Dr. Block is one of the world's preeminent nephrologists and a trailblazer in leading clinical development for drugs focused on enhancing the care and treatment of patients suffering from chronic kidney disease (CKD) and end stage renal disease (ESRD) patients on dialysis. Dr. Block has participated extensively in guiding the development of tenapanor, Ardelyx's lead product candidate in Phase 3 clinical trials for the treatment of hyperphosphatemia in ESRD patients on dialysis.
FREMONT, Calif., March 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced the publication in the Journal of the American Society of Nephrology (JASN) of results from the first of two Phase 3 pivotal trials for tenapanor to treat hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis. During the treatment period, 164 patients completed treatment in one of three randomized dosing groups (3, 10 and 30 mg titration) of tenapanor twice daily.
Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia FREMONT, Calif. , March 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused ...
I've been keeping an eye on Ardelyx, Inc. (NASDAQ:ARDX) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe ARDXRead More...
FREMONT, Calif., Feb. 21, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:30 p.m. ET on Thursday, Feb. 28, 2019 at the Lotte New York Palace Hotel in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
FREMONT, Calif., Feb. 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX) (Ardelyx) today announced that its collaboration partner in Japan, Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151) (Kyowa Hakko Kirin), has initiated a Phase 2 clinical study in Japan evaluating tenapanor for the treatment of hyperphosphatemia patients on dialysis. The achievement of this development milestone triggers a $5 million payment to Ardelyx.
In this article I am going to calculate the intrinsic value of Ardelyx, Inc. (NASDAQ:ARDX) by taking the expected future cash flows and discounting them to today's value. I will Read More...
Is Ardelyx Inc (NASDAQ:ARDX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from industry insiders. They sometimes fail miserably but historically their consensus stock picks outperformed the market after […]
The big shareholder groups in Ardelyx Inc (NASDAQ:ARDX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership Read More...
FREMONT, Calif., Nov. 13, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor, Ardelyx's lead product candidate, is a minimally-systemic small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium transporter NHE3 and reduce sodium uptake from the gut. Ardelyx's NDA submission is supported by a clinical package encompassing more than 3,100 patients and healthy volunteers who have participated in Ardelyx trials and an extensive clinical and preclinical data package supporting the excellent safety profile.
The Fremont, California-based company said it had a loss of 39 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019 FREMONT, Calif. , Nov. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights ...
FREMONT, Calif., Oct. 26, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in combination with sevelamer, the current standard-of-care phosphate binder treatment for hyperphosphatemia, or elevated serum phosphorus. The data, showing that the combination meaningfully reduced serum phosphorus, were presented today in a poster titled "Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats," at the American Society of Nephrology (ASN) Annual Meeting.